The STR profile of this cell line matches that of its parental cell line ATCC(R) Catalog No. CCL-185a. A549 is a human lung carcinoma cell line isolated in 1972 from a lung tumor of a male patient suffering from carcinoma.
Storage: -196C
Application: This product is a human A549 adenocarcinoma cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr(R)Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user's choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.
Legal Information: CompoZr is a registered trademark of Sigma-Aldrich Co. LLC